公开(公告)号：US20230348561A1

公开(公告)日：2023-11-02

申请号：US18309062

申请日：2023-04-28

Applicant: IMMATICS US, INC.

Inventor： Erik FARRAR ,  Justin GUNESCH ,  Melinda MATA ,  Mohammad HOSSAIN ,  Mamta KALRA ,  Gagan BAJWA

IPC: C07K14/725 ,  C07K14/705 ,  C12N15/63 ,  A61P37/04

CPC classification number: C07K14/7051 ,  C07K14/70517 ,  C12N15/63 ,  A61P37/04

Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with dominant negative TGFβ Receptor (“dnTGFβR”) polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for dnTGFβR polypeptides, vectors, and associated methods thereof. The present disclosure further provides for modified CD8 polypeptides, vectors, and associated methods of making and using the same.

公开(公告)号：US20240066127A1

公开(公告)日：2024-02-29

申请号：US18308427

申请日：2023-04-27

Applicant: IMMATICS US, INC.

Inventor： Justin GUNESCH ,  Melinda MATA ,  Mamta KALRA ,  Gagan BAJWA

IPC: A61K39/00 ,  A61K39/39 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725

CPC classification number: A61K39/4635 ,  A61K39/39 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4632 ,  A61K39/464489 ,  A61P35/00 ,  C07K14/54 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70517 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561

Abstract: The present disclosure relates to cells capable of co-expressing one or any combination of T cell receptors (“TCR”), CD8 polypeptides, interleukin 12 (IL-12) polypeptides, interleukin 15 (IL-15) polypeptides, and/or interleukin 18 (IL-18) polypeptides, and the use thereof in adoptive cellular therapy (“ACT”). The present disclosure further provides for modified CD8 sequences, IL-12 sequences, IL-15 sequences, IL-18 sequences, vectors, compositions, transformed T cells, and associated methods thereof.

公开(公告)号：US20220056411A1

公开(公告)日：2022-02-24

申请号：US17409504

申请日：2021-08-23

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Gagan BAJWA ,  Thomas LUCAS ,  Ali MOHAMED ,  Steffen WALTER

IPC: C12N5/0783 ,  C12N15/85 ,  C07K14/725

Abstract: A method of producing an engineered T cell population includes obtaining a cell population comprising a CD8+ T cell, isolating the CD8+ T cell from the obtained cell population, activating the isolated CD8+ T cell, introducing a nucleic acid encoding a T cell receptor (TCR) binding to an antigen in a complex with an MHC molecule into the activated CD8+ T cell, and expanding the introduced CD8+ T cell to obtain the engineered T cell population.

公开(公告)号：US20230348548A1

公开(公告)日：2023-11-02

申请号：US18309080

申请日：2023-04-28

Applicant: IMMATICS US, INC.

Inventor： Justin GUNESCH ,  Mohammad HOSSAIN ,  Gagan BAJWA ,  Melinda MATA ,  Mamta KALRA

IPC: C12N5/0783 ,  C12N15/86 ,  C07K14/705 ,  C07K16/00 ,  C07K14/54 ,  C07K14/725 ,  A61K39/00 ,  A61K39/39

CPC classification number: C07K14/5443 ,  A61K39/39 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4621 ,  A61K39/4632 ,  A61K39/4633 ,  A61K39/4635 ,  A61K39/4643 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/00 ,  C12N5/0636 ,  C12N15/86 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561 ,  A61K2039/55588 ,  C12N2502/1121 ,  C12N2740/15043

Abstract: The present disclosure relates to cells capable of co-expressing T cell receptors (“TCR”) together with membrane-bound IL-15 polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified IL-15, IL-15Rα, IL-15/IL-15Rα fusion polypeptide, and IL-15Rα/IL-15 fusion polypeptide sequences, vectors, and associated methods of making and using the same. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods of making and using the same.

公开(公告)号：US20220202862A1

公开(公告)日：2022-06-30

申请号：US17563599

申请日：2021-12-28

Applicant: Immatics US, Inc.

Inventor： Gagan BAJWA ,  Mamta KALRA ,  Melinda MATA

IPC: A61K35/17 ,  C12N15/86 ,  C12N5/0783 ,  C07K14/725 ,  C07K14/705

Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.